Neisvac-C

Tetanus toxoid, algeldrate, Neisseria meningitidis group C (de-O-acetylated) polysaccharide, the active ingredient in Neisvac-C, is a vaccine presented as a lyophilized powder for reconstitution for intramuscular use. It provides active immunity against tetanus and Neisseria meningitidis group C infections in individuals requiring prophylactic immunization.

GNH USA supplies Neisvac-C as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neisvac-C is indicated for immunization against bacterial toxins and encapsulated organisms. - Tetanus: induces protective antibodies that neutralize tetanus toxin and prevent disease. - Neisseria meningitidis group C infection: stimulates immunity against the group C polysaccharide to reduce risk of invasive meningococcal disease. - Combined tetanus‑meningococcal prophylaxis: offers simultaneous protection against both tetanus and meningococcal group C in a single injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema that resolves within a few days. - Fever: transient low‑grade temperature elevation. - Headache or fatigue: general malaise following vaccination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder characterized by muscle weakness. - Seizures: uncommon neurologic event post‑vaccination. - Severe hypotension or shock: rare circulatory compromise needing urgent care.

Precautions should be observed before administering Neisvac-C. - Allergy assessment: avoid in persons with known hypersensitivity to any component, especially tetanus toxoid or algeldrate. - Pregnancy: use only if the expected benefit outweighs potential risk; consult a healthcare professional. - Immunocompromised patients: vaccine may be less immunogenic; monitor serologic response. - Concurrent immunizations: may be given with other vaccines at separate anatomical sites. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be considered. Major Interactions (Avoid): - Live vaccines: avoid simultaneous administration as immune interference may occur. - Immunoglobulin therapy: may reduce vaccine efficacy if given within two weeks of vaccination. - Blood products: may interfere with antibody development if administered within four weeks. Moderate Interactions (Monitor Closely): - Antipyretics: may mask post‑vaccination fever; use as needed. - Immunosuppressive drugs: may diminish immune response; consider monitoring antibody titres.